Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells

Endocrinology

Volumn 152, Issue 8, 2011, Pages 3143-3154

  Ning, Junyu ^a,b   Xi, Gang ^a   Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Beijing Centers for Diseases Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SHORT HAIRPIN RNA; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC TRANSDUCTION; HYPERGLYCEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES; VASCULAR SMOOTH MUSCLE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; HYPERGLYCEMIA; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHOSERINE; PROTO-ONCOGENE PROTEINS C-AKT; SWINE;

EID: 79960746886     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-0155     Document Type: Article

References (45)

1. Maile LA, Capps BE, Ling Y, Xi G, Clemmons DR 2007 Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinology 148:2435-2443 (Pubitemid 46997046)
2. Radhakrishnan Y, Maile LA, Ling Y, Graves LM, Clemmons DR 2008 Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells. J Biol Chem 283:16320-16331
3. Hardie DG, Carling D, Carslon M 1998 The AMP-activated/SNF1 protein kinase subfamily:metabolic sensors of the eukaryotic cell? Annu Rev Biochem 67:821-855
4. Carling D 2004 The AMP-activated protein kinase cascade: a unifying system for energy control. Trends Biochem Sci 29:18-24 (Pubitemid 38068476)
5. Inoki K, Zhu T, Guan KL 2003 TSC2 mediates cellular energy response to control cell growth and survival. Cell 115:577-590 (Pubitemid 37506046)
6. Tzatsos A, Tsichlis PN 2007 Energy depletion inhibits phosphatdylinositol 3-kinase/AKt signaling and induces apoptosis via AMP activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 282:18069-18082 (Pubitemid 47100251)
7. Ning J, Clemmons DR 2010 AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol Endocrinol 24:1218-1229
8. Canabal DD, Potian JG, Duran RG, McArdle JJ, Routh VH 2007 Hyperglycemia impairs glucose and insulin regulation of nitric oxide production in glucose-inhibited neurons in the ventromedial hypothalamus. Am J Physiol Regul Integr Comp Physiol 293:R592-R600 (Pubitemid 47205039)
9. Xi G, Shen X, Clemmons DR 2008 p66shc negatively regulates insulin-like growth factor I signal transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 leading to impaired growth factor receptor-bound protein-2 membrane recruitment. Mol Endocrinol 22:2162-2175
10. Nam TJ, Busby Jr WH, Rees C, Clemmons DR 2000 Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology 141:1100-1106 (Pubitemid 32266071)
11. Maile LA, Capps BE, Miller EC, Aday AW, Clemmons DR 2008 Integrin-associated protein association with SRC homology 2 domain containing tyrosine phosphatase substrate 1 regulates IGF-I signaling in vivo. Diabetes 57:2637-2643
12. Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher P, Ruderman NB, Cohen RA 2004 AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 279:47898-47905 (Pubitemid 39540941)
13. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, Sartorelli V 2008 Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 14:661-673
14. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR 2003 Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 278:39422-39427 (Pubitemid 37248497)
15. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N 2005 Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 280:32081-32089 (Pubitemid 41361813)
16. Maile LA, Capps BE, Miller EC, Allen LB, Veluvolu U, Aday AW, Clemmons DR 2008 Glucose regulation of integrin-associated protein cleavage controls the response of vascular smooth muscle cells to insulin-like growth factor-I. Mol Endocrinol 22:1226-1237 (Pubitemid 351629621)
17. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, Kahana JA, Kral AM, Leander K, Lee LL, Malinowski J, McAvoy EM, Nahas DD, Robinson RG, Huber HE 2005 Identification and characterization of pleckstrin-homology- domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385:399-408 (Pubitemid 40165072)
18. Ren H, Yin P, Duan C 2008 IGFBP-5 regulates muscle cell differentiation by binding to IGF-II and switching on the IGF-II autoregulation loop. J Cell Biol 182:979-991
19. Imai Y, Clemmons DR 1999 Roles of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in stimulation of vascular smooth muscle cell migration and deoxyribonucleic acid synthesis by insulin-like growth factor-I. Endocrinology 140:4228-4235 (Pubitemid 30647121)
20. He G, Sung YM, Digiovanni J, Fischer SM 2006 Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res 66:1873-1878
21. Kim J, Yoon MY, Choi SL, Kang I, Kim SS, Kim YS, Choi YK, Ha J 2001 Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway. J Biol Chem 276:19102-19110
22. Treins C, Murdaca J, Van Obberghen E, Giorgetti-Peraldi S 2006 AMPK activation inhibits the expression of HIF-1α induced by insulin and IGF-I. Biochem Biophys Res Commun 342:1197-1202
23. Long YC, Cheng Z, Copps KD, White MF 2011 Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways. Mol Cell Biol 31:430-441
24. Liang KW, Yin SC, Ting CT, Lin SJ, Hsueh CM, Chen CY, Hsu SL 2008 Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. Eur J Pharmacol 590:343-354
25. Shen X, Xi G, Radhakrishnan Y, Clemmons DR 2010 PDK1 recruitment to the SHPS-1 signaling complex enhances insulin-like growth factor-I-stimulated AKT activation and vascular smooth muscle cell survival. J Biol Chem 285:29416-29424
26. Horman S, Vertommen D, Heath R, Neumann D, Mouton V, Woods A, Schlattner U, Wallimann T, Carling D, Hue L, Rider MH 2006 Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 281: 5335-5340
27. Berggreen C, Gormand A, Omar B, Degerman E, Göransson O 2009 Protein kinase B activity is required for the effects of insulin on lipid metabolism in adipocytes. Am J Physiol Endocrinol Metab 296: E635-E646
28. Soltys CL, Kovacic S, Dyck JR 2006 Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol 290:H2472-H2479 (Pubitemid 43846078)
29. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS 2007 A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 292: F617-F627 (Pubitemid 46220529)
30. Kitada M, Kume S, Imaizumi N, Koya D 2011 Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60:634-643
31. Kim JE, Choi HC 2010 Losartan inhibits vascular smooth muscle cell proliferation through activation of AMP-activated protein kinase. Korean J Physiol Pharmacol 14:299-304
32. Hopkins TA, Ouchi N, Shibata R, Walsh K 2007 Adiponectin actions in the cardiovascular system. Cardiovasc Res 74:11-18 (Pubitemid 46366942)
33. Kim SY, Jeoung NH, Oh CJ, Choi YK, Lee HJ, Kim JH, Kim YJ, Hwang JH, Tadi S, Yim YH, Lee KU, Park KG, Huh S, Min KN, Jeong KH, Park MG, Kwak TH, Kweon GR, Inukai K, Shong M, Lee IK 2009 Activation of NAD(P)H:quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circ Res 104:824-850
34. Kim J, Wende AR, Sena S, Theobald HA, Soto J, Sloan C, Wayment BE, Litwin SE, Holzenberger M, LeRoith D, Abel ED 2008 Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endocrinol 22:2531-2543
35. Foster AD, Yellen P, Xu L, Saqcena M 2011 Regulation of G1 cell cycle progression: Distinguishing the restriction point from a nutrient-sensing cell growth checkpoints. Genes and Cancer 1:1124-1131
36. Motoshima H, Goldstein BJ, Igata M, Araki E 2006 AMPK and cell proliferation: AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574:63-71 (Pubitemid 43905797)
37. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB 2005 AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18:283-293 (Pubitemid 41350534)
38. Feng Z 2010 p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol 2:a001057
39. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, Levine AJ 2007 The regulation of AMPK β1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 67:3043-3053 (Pubitemid 46724841)
40. Chakravarthy MV, Abraha TW, Schwartz RJ, Fiorotto ML, Booth FW2000 Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3′kinase/Akt signaling pathway. J Biol Chem 17:35942-35952
41. McApline CS, Bowes AJ, Werstuck GH 2010 Diabetes, hyperglycemia and accelerated atherosclerosis: evidence supporting a role for endoplasmic reticulum (ER) stress signaling. Cardiovasc Hematol Disord Drug Targets 10:151-157
42. Luo Z, Zang M, Guo W 2010 AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 6:457-470
43. Fay JR, Steele V, Crowell JA 2009 Energy homeostasis and cancer prevention: the AMP-activated protein kinase. Cancer Prev Res (Phila) 2:301-309
44. Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S 2011 Combination of mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 17:871-879
45. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D 2010 Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer 17:941-951